Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).

Trial Details

NCT ID
NCT05790213
Phase
PHASE2
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Androgen Deprivation Therapy (ADT)
  • Focal prostate ablation (focal therapy)
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Subjects must have intermediate-risk PCa as defined by the below criteria:
  • a. Favorable intermediate-risk PCa: i. ≤ clinical stage T2c, GG2, and PSA ≤ 10 ng/mL, and \<50% positive biopsy cores with PCa b. Unfavorable inter…
  • No mpMRI evidence of extra-prostatic extension (EPE) or seminal vesicle invasion, and if seminal vesical invasion is suspected, it must be excluded…
  • Subjects must have chosen to get Focal Therapy for the treatment of prostate cancer.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →